Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207634 · ClinicalTrials.gov registry record · Phase 3
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,974
- Enrollment target
NCT02207634 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 1,974 participants.
The verdict
NCT02207634, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,974 participants
- Enrollment target
Study Summary
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
Interventions
- DRUG Placebo
- BIOLOGICAL Evolocumab
- DRUG Background Statin Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,974 participants |
| Start Date | 2014-09-10 |
| Est. Completion | 2016-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207634
The ClinicalTrials.gov registry entry for NCT02207634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,974 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02207634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207634 about?
NCT02207634 is a clinical study titled "Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects". This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
What is the current status of trial NCT02207634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,974 participants. The study started on 2014-09-10. Estimated completion is 2016-11-11.
What interventions are being tested in trial NCT02207634?
The interventions under investigation include: Placebo (DRUG), Evolocumab (BIOLOGICAL), Background Statin Therapy (DRUG).
Who is sponsoring clinical trial NCT02207634?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.